Design and synthesis of piperazinylpyrimidinones as novel selective 5-HT2C agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 18, 2009, Pages 5346-5350

  Andrews, Mark D ^a   Green, Martin P ^a   Allerton, Charlotte M N ^a   Batchelor, David V ^a   Blagg, Julian ^b   Brown, Alan D ^a   Gordon, David W ^a   McMurray, Gordon ^a   Millns, Daniel J ^a   Nichols, Carly L ^a   Watson, Lesa ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

5 HT2C; Agonist; CNS penetration; Pyrimidinone

Indexed keywords

PIPERAZINYLPYRIMIDINONE DERIVATIVE; SEROTONIN 2A RECEPTOR; SEROTONIN 2B RECEPTOR; SEROTONIN 2C AGONIST; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; DOG; DRUG DESIGN; DRUG EFFECT; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; NONHUMAN; REACTION ANALYSIS; RECEPTOR AFFINITY; STRESS INCONTINENCE; STRUCTURE ANALYSIS;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DOGS; HUMANS; PYRIMIDINONES; RECEPTOR, SEROTONIN, 5-HT2B; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN 5-HT2 RECEPTOR AGONISTS; SEROTONIN RECEPTOR AGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP; URETHRA; URINARY INCONTINENCE;

EID: 68949105596     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.07.133     Document Type: Article

References (24)

1. Hoyer D., and Martin G. Neuropharmacology 36 (1997) 419
2. Bishop M.J., and Nilsson B.M. Exp. Opin. Ther. Patents 13 (2003) 1691
3. Ramage A.G. Br. J. Pharmacol. 147 (2006) S120
4. Wang Y., Serradell N., and Bolos J. Drugs Future 32 (2007) 766
5. Smith B.M., Smith J.M., Tsai J.H., Schultz J.A., Gilson C.A., Estrada S.A., Chen R.R., Park D.M., Prieto E.B., Gallardo C.S., Sengupta D., Dosa P.I., Covel J.A., Ren A., Webb R.R., Beeley N.R.A., Martin M., Morgan M., Espitia S., Saldana H.R., Bjenning C., Whelan K.T., Grottick A.J., Menzaghi F., and Thomsen W.J. J. Med. Chem. 51 (2008) 305
6. Thomsen W.J., Grottick A.J., Menzaghi F., Reyes-Saldana H., Espitia S., Yuskin D., Whelan K., Martin M., Morgan M., Chen W., Al-Sham H., Smith B., Chalmers D., and Behan D. J. Pharm. Exp. Ther. 325 (2008) 577
7. Ramamoorthy, P. S.; Beyer, C.; Brennan, J.; Dunlop, J.; Gove, S.; Grauer, S.; Harrison, B. L.; Lin, Q.; Malberg, J.; Marquis, K.; Mazandarani, H.; Piesla, M.; Pulicicchio, C.; Rosenzwieg-Lipson, S.; Sabb, A.-M.; Schechter, L.; Stack, G.; Zhang, J. Abstracts of Papers, 231st ACS National Meeting, Atlanta, GA, United States, March 26-30, 2006; MEDI-021.
8. Nichols D.E. Pharmacol. Ther. 101 (2004) 131
9. Villalon C.M., and Centurion D. Naunyn-Schmiedeberg's Arch. Pharmacol. 376 (2007) 45
10. Roth B.L. N. Engl. J. Med. 356 (2007) 6
11. Edlund P.O., and Baranczewski P. J. Pharm. Biomed. Anal. 34 (2004) 1079
12. Kalgutkar A.S., Bauman J.N., McClure K.F., Aubrecht J., Cortina S.R., and Paralkar J. Bioorg. Med. Chem. Lett. 19 (2009) 1559
13. Increased lipophilicity has been strongly linked with poorer ADME properties and an increased risk of problems with selectivity and toxicology. Hughes J.D., Blagg J., Price D.A., Bailey S., DeCrescenzo G.A., Devraj R.V., Ellsworth E., Fobian Y.M., Gibbs M.E., Gilles R.W., Greene N., Huang E., Krieger-Burke T., Loesel J., Wager T., Whiteley L., and Zhang Y. Bioorg. Med. Chem. Lett. 18 (2008) 4872
14. Gleeson M.P. J. Med. Chem. 51 (2008) 817
15. Leeson P.D., and Springthorpe B. Nat. Rev. Drug Disc. 6 (2007) 881
16. Allerton, C. M. N.; Andrews, M. D.; Blagg, J.; Ellis, D.; Evrard, E.;Green, M. P.; Liu, K.; McMurray, G.; Ralph, M.; Sanderson, V.; Ward, R.; Watson, L. Bioorg. Med. Chem. Lett. 2009, preceding article.
17. Mahar Doan K.M., Humphreys J.E., Webster L.O., Wring S.A., Shampine L.J., Serabjit-Singh C.J., Adkison K.K., and Polli J.W. J. Pharm. Exp. Ther. 303 (2002) 1029
18. Andrews, M.; Blagg, J.; Brennan, P.; Fish, P. V.; Roberts, L.; Storer, R. I.; Whitlock, G. A. WO patent 117169, 2008.
19. Elvidge J.A., and Zaidi N.A. J. Chem. Soc. (C) 17 (1968) 2188
20. O'Neill A.B., Buckner S.A., Brune M.E., Milicic I., Daza A.V., Gauvin D.M., Altenbach R.J., Meyer M.D., Williams M., Sullivan J.P., and Brioni J.G. Life Sci. 70 (2001) 181
21. Conlon, K.; Christy, C.; Westbrook, S.; Whitlock, G.; Roberts, L.; Stobie, A.; McMurray, G. J. Pharmacol. Exp. Ther., in press. doi:10.1124/jpet.109.154963.
22. Kim S., and Yi K.Y. J. Org. Chem. 51 (1986) 2613
23. Compound 16 was synthesised by the same method as used for methyl 3-oxo-5-phenylpentanoate, using 3-chlorobenzyl bromide instead of benzyl chloride,. Huckin S.N., and Weiler L. J. Am. Chem. Soc. 96 (1974) 1082
24. The required amidines were either commercially available or readily synthesised from the corresponding nitriles using the Pinner reaction,. Roger R., and Neilson D.G. Chem. Rev. 61 (1961) 179